Premium
Altered course of Plasmodium berghei infection by nifedipine treatment
Author(s) -
KALRA ANJU,
DUBEY M. L.,
GANGULY N. K.,
MOHAN K.,
MAHAJAN R. C.
Publication year - 1993
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1699-0463.1993.tb00163.x
Subject(s) - nifedipine , plasmodium berghei , chloroquine , malaria , chemoprophylaxis , pharmacology , calcium channel , parasite hosting , drug resistance , medicine , drug , calcium , biology , immunology , microbiology and biotechnology , world wide web , computer science
The effect of nifedipine (a calcium channel blocker) on the course of P. berghei infection was examined. It was observed that mice receiving a daily dose of 0.015 mg/kg of nifedipine had significantly shorter prepatent, patent and survival periods as compared to untreated P. berghei ‐infected animals (p < 0.001). This shows that the calcium channel blockers, in addition to possessing the property of reversing drug resistance during combined therapy with chloroquine, may also alter the pathophysiology of malaria infection. The decreased resistance of the host to the invading parasite suggests that the effect of CCB on the host‐parasite interaction in human malaria needs to be investigated further before CCB can be used in combination with chloroquine for the treatment of chloroquine‐resistant malaria or for chemoprophylaxis.